Steve Schonfeld’s Gain Therapeutics GANX Stock Holding History

Steve Schonfeld’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-24,500	Closed	-$47.5K	–	2739
2026 Q1	$47.5K	Buy	+24,500	New	+$53.3K	﹤0.01%	1973

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Steve Schonfeld's GANX Position: Q2 2026 in Review

Steve Schonfeld sold out of Gain Therapeutics (GANX) in Q2 2026, closing a stake of 24,500 shares — an estimated $47.5K sold.

Steve Schonfeld first reported a position in GANX in Q1 2026 and held it in 1 quarter. The position peaked at $47.5K in Q1 2026. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Steve Schonfeld reported no remaining Gain Therapeutics position as of Q2 2026 after selling out during the quarter.
Steve Schonfeld sold 24,500 Gain Therapeutics shares in Q2 2026, an estimated $47.5K.
Steve Schonfeld first reported a position in Gain Therapeutics in Q1 2026 and held it in 1 quarter.
Steve Schonfeld's Gain Therapeutics position peaked at $47.5K in Q1 2026.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.